The Cost-effectiveness of Valganciclovir Prophylaxis Versus Preemptive Therapy in CMV R+ Kidney Transplant Recipients Over the First Year Posttransplantation

The Cost-effectiveness of Valganciclovir Prophylaxis Versus Preemptive Therapy in CMV R+ Kidney Transplant Recipients Over the First Year Posttransplantation

Background. In kidney transplant recipients with positive serology (R+) for the cytomegalovirus (CMV), 2 strategies are used to prevent infection, whose respective advantages over the other are still debated. This study aimed to evaluate the cost-effectiveness and cost utility of antiviral prophylax...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit: Claire Villeneuve, PhD, Jean-Phillipe Rerolle, MD, Lionel Couzi, MD, PhD, Pierre-Francois Westeel, MD, Isabelle Etienne, MD, Laure Esposito, MD, Nassim Kamar, MD, PhD, Mathias Büchler, MD, PhD, Antoine Thierry, MD, PhD, Pierre Marquet, MD, PhD, Caroline Monchaud, PharmD, PhD
Materiálatiipa: Artihkal
Giella:English
Almmustuhtton: Wolters Kluwer 2024-08-01
Ráidu:Transplantation Direct
Liŋkkat:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001678

Interneahtta

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001678

Geahča maid